Apeloa Pharmaceutical Co Ltd (000739) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apeloa Pharmaceutical Co Ltd (000739) has a cash flow conversion efficiency ratio of 0.070x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥446.18 Million ≈ $65.29 Million USD) by net assets (CN¥6.35 Billion ≈ $928.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 000739 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Apeloa Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Apeloa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Apeloa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apeloa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Expressway Co Ltd
SHG:600012
|
0.072x |
|
Momentum Metropolitan Holdings Ltd
JSE:MTM
|
0.051x |
|
Aura Minerals Inc
TO:ORA
|
0.571x |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
0.051x |
|
Hypera S.A
SA:HYPE3
|
0.014x |
|
Xuzhou Handler Special Vehicle Co Ltd
SHE:300201
|
0.029x |
|
ATS CORP
TO:ATS
|
0.064x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
Annual Cash Flow Conversion Efficiency for Apeloa Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Apeloa Pharmaceutical Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Apeloa Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.35 Billion ≈ $928.67 Million |
CN¥1.23 Billion ≈ $180.09 Million |
0.194x | +8.29% |
| 2024-12-31 | CN¥6.75 Billion ≈ $987.72 Million |
CN¥1.21 Billion ≈ $176.88 Million |
0.179x | +8.18% |
| 2023-12-31 | CN¥6.23 Billion ≈ $911.71 Million |
CN¥1.03 Billion ≈ $150.92 Million |
0.166x | -31.10% |
| 2022-12-31 | CN¥5.52 Billion ≈ $807.64 Million |
CN¥1.33 Billion ≈ $194.05 Million |
0.240x | +98.74% |
| 2021-12-31 | CN¥5.06 Billion ≈ $740.44 Million |
CN¥611.75 Million ≈ $89.52 Million |
0.121x | -49.90% |
| 2020-12-31 | CN¥4.39 Billion ≈ $642.49 Million |
CN¥1.06 Billion ≈ $155.04 Million |
0.241x | -33.15% |
| 2019-12-31 | CN¥3.77 Billion ≈ $551.37 Million |
CN¥1.36 Billion ≈ $199.02 Million |
0.361x | +45.01% |
| 2018-12-31 | CN¥3.35 Billion ≈ $489.52 Million |
CN¥832.69 Million ≈ $121.85 Million |
0.249x | +261.87% |
| 2017-12-31 | CN¥3.05 Billion ≈ $446.31 Million |
CN¥209.80 Million ≈ $30.70 Million |
0.069x | -0.24% |
| 2016-12-31 | CN¥2.62 Billion ≈ $382.88 Million |
CN¥180.42 Million ≈ $26.40 Million |
0.069x | -62.22% |
| 2015-12-31 | CN¥2.42 Billion ≈ $353.65 Million |
CN¥441.16 Million ≈ $64.56 Million |
0.183x | -46.49% |
| 2014-12-31 | CN¥2.31 Billion ≈ $337.43 Million |
CN¥786.64 Million ≈ $115.11 Million |
0.341x | +232.78% |
| 2013-12-31 | CN¥1.86 Billion ≈ $271.86 Million |
CN¥190.45 Million ≈ $27.87 Million |
0.103x | -58.33% |
| 2012-12-31 | CN¥1.37 Billion ≈ $199.83 Million |
CN¥335.90 Million ≈ $49.15 Million |
0.246x | -25.14% |
| 2011-12-31 | CN¥1.23 Billion ≈ $180.21 Million |
CN¥404.62 Million ≈ $59.21 Million |
0.329x | +119.48% |
| 2010-12-31 | CN¥808.57 Million ≈ $118.32 Million |
CN¥121.05 Million ≈ $17.71 Million |
0.150x | -42.88% |
| 2009-12-31 | CN¥794.78 Million ≈ $116.30 Million |
CN¥208.30 Million ≈ $30.48 Million |
0.262x | +112.87% |
| 2008-12-31 | CN¥768.11 Million ≈ $112.40 Million |
CN¥94.57 Million ≈ $13.84 Million |
0.123x | -46.98% |
| 2007-12-31 | CN¥750.11 Million ≈ $109.76 Million |
CN¥174.20 Million ≈ $25.49 Million |
0.232x | -36.48% |
| 2006-12-31 | CN¥436.05 Million ≈ $63.81 Million |
CN¥159.43 Million ≈ $23.33 Million |
0.366x | +72.33% |
| 2005-12-31 | CN¥411.93 Million ≈ $60.28 Million |
CN¥87.40 Million ≈ $12.79 Million |
0.212x | +65.59% |
| 2004-12-31 | CN¥371.08 Million ≈ $54.30 Million |
CN¥47.54 Million ≈ $6.96 Million |
0.128x | -60.01% |
| 2003-12-31 | CN¥328.83 Million ≈ $48.12 Million |
CN¥105.36 Million ≈ $15.42 Million |
0.320x | +3243.46% |
| 2002-12-31 | CN¥293.69 Million ≈ $42.98 Million |
CN¥2.81 Million ≈ $411.85K |
0.010x | +536.80% |
| 2001-12-31 | CN¥259.70 Million ≈ $38.00 Million |
CN¥-569.79K ≈ $-83.38K |
-0.002x | -108.50% |
| 2000-12-31 | CN¥274.23 Million ≈ $40.13 Million |
CN¥7.08 Million ≈ $1.04 Million |
0.026x | +138.74% |
| 1999-12-31 | CN¥307.93 Million ≈ $45.06 Million |
CN¥-20.52 Million ≈ $-3.00 Million |
-0.067x | -150.12% |
| 1998-12-31 | CN¥226.31 Million ≈ $33.12 Million |
CN¥30.10 Million ≈ $4.40 Million |
0.133x | -- |
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&… Read more